Johnson & Johnson Gains EU Approval for IMAAVY (Nipocalimab) in Generalized Myasthenia Gravis

Sun Pharma Launches ILUMYA in India for Psoriasis Patients | iPharmaCenter

US FDA Accepts AstraZeneca’s Baxdrostat for Priority Review in Resistant Hypertension

FDA Approves Jaypirca for Relapsed or Refractory CLL/SLL Previously Treated with Covalent BTK Inhibitors | iPharmaCenter

Best‑Selling Cancer Drugs 2025: Top 10 Brands, Uses and MOA | Best selling cancer drugs | 2025 | iPharmaCenter

Top 10 pharmaceutical companies by revenues | 2025 | iPharmaCenter

CTAD 2025: Eisai Highlights Etalanetug Tau Reductions and LEQEMBI Protofibril Data; Merck Shares Early MK-2214, MK-1167 Results | Clinical Trials on Alzheimer's Disease 2025 | iPharmaCenter

Bristol Myers Squibb Extends Cobenfy Trial in Alzheimer’s Psychosis After DMC Recommendation | iPharmaCenter

Dual Special Needs Plans (D-SNPs) and Key 2026 Changes: What Dual Eligibles Need to Know During Medicare Enrollment | iPharmaCenter

Eli Lilly Cuts Zepbound Prices on Single‑Dose Vials to Expand Obesity Drug Access in the US | iPharmaCenter

US–Swiss Tariff Cap Impact on Pharma: How the New US–Swiss Tariff Cap Shapes Pharma and Health Security

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

NICE increased cost effectiveness threshold from £20,000-£30,000/QALY to £25,000-£35,000/QALY

CMS Launches ACCESS Outcome-Aligned Payment Model for High-Burden Chronic Conditions | iPharmaCenter

FDA Clears Imfinzi as First Perioperative Immunotherapy for Resectable Gastric and GEJ Cancers | iPharmaCenter

EU clears Dupixent as first targeted CSU therapy in over a decade | iPharmaCenter

FDA Greenlights Kygevvi as Pioneering Therapy for Thymidine Kinase 2 Deficiency in Adults and Kids | iPharmaCenter

China NMPA Approves Pfizer’s Matazisimab (You Ruiting) for Routine Prophylaxis in Hemophilia Patients with Inhibitors | iPharmaCenter

CMS Projects Billions in Future Savings for Seniors; Maximum Fair Price (MFP) Negotiation Policy Originated Under Biden Administration | iPharmaCenter

CMS Introduces Proposed Rule to Elevate Quality and Access in Medicare Advantage and Part D | iPharmaCenter

NICE Approves Autolus’ Obe-cel CAR-T Therapy for Adults with Rare Blood Cancer | iPharmaCenter

BMS' Breyanzi CAR-T Therapy Approved for Treating Mantle Cell Lymphoma | iPharmaCenter

Novartis Receives FDA Approval for Itvisma, Expanding Access to Gene Replacement Therapy for People of All Ages Living with Spinal Muscular Atrophy (SMA)

The Pharma Top 10: Highest Revenue Drugs of 2025 (Official Sales Data & Analysis) | Top selling pharmaceutical drugs | iPharmaCenter

Germany Signals Major Health System Overhaul as Minister Warken Warns of Growing Deficits | iPharmaCenter

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

Novartis hopes its cancer drugs drive revenues until 2030 | iPharmaCenter

Roche’s Giredestrant Leads the Way as First Oral SERD to Improve Outcomes in Early Breast Cancer | iPharmaCenter

FDA Approves Epkinly in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma | iPharmaCenter

American College of Rheumatology (ACR) Convergence | Chicago | 2025 | iPharmaCenter

European Society for Medical Oncology (ESMO) Congress | ESMO 2025 | News | Updates | iPharmaCenter

Lilly’s Oral GLP-1 Orforglipron Shows Superior Results in Two Phase 3 Trials for Type 2 Diabetes | iPharmaCenter

Novo Nordisk Acquires Akero Therapeutics for $4.7 Billion, Expanding Its MASH Portfolio with First-in-Class FGF21 Analogue

FDA Approves Johnson & Johnson’s Simponi (golimumab) as the First Monthly Maintenance Therapy for Pediatric Ulcerative Colitis

Daiichi Sankyo Advances Breast Cancer Portfolio Expansion with ENHERTU approaval in Japan and DATROWAY's positive study

Novartis Ushers in a New Era with FDA Approval of Rhapsido (Remibrutinib) for Chronic Spontaneous Urticaria

AbbVie's Latest Clinical Trial for Alopecia Areata Shows Positive Results | iPharmaCenter

FDA Clears Novo Nordisk’s Wegovy for MASH Treatment | iPharmaCenter

FDA Approves GSK’s Nucala for COPD Patients with Eosinophilic Inflammation

American College of Cardiology’s (ACC) Annual Scientific Session & Expo | Chicago | News | Updates

Novartis Secures FDA Accelerated Approval for Vanrafia, a Novel Treatment for Proteinuria in IgA Nephropathy

FDA Approves Novartis' Pluvicto for Earlier Treatment of Prostate Cancer | iPharmaCenter

Conference on Retroviruses and Opportunistic Infections (CROI 2025) | San Francisco | iPharmaCenter

AstraZeneca Secures CDSCO Approval for Durvalumab in Limited-Stage Small Cell Lung Cancer Treatment | iPharmaCenter

American Academy of Dermatology (AAD) Annual Meeting | 2025 | News | Updates | iPharmaCenter

Tevimbra Receives U.S. Approval for First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy | iPharmaCenter

2025 AAAAI / WAO Joint Congress | American Academy of Allergy, Asthma & Immunology | iPharmaCenter

Sanofi’s Innovative Treatment Rezurock Gains Approval in India for Chronic Graft-Versus-Host Disease (cGVHD) | iPharmaCenter

Winter Clinical Dermatology Conference – Hawaii (WCH) | 2025 | iPharmaCenter

Top Drug Launches to Watch in 2025 | iPharmaCenter